Michèle Lesieur

About Michèle Lesieur

Michèle Lesieur is an experienced executive in the healthcare and medical imaging sector, known for combining operational leadership, corporate transformation, and listed-company governance. At Guerbet, a global specialist in contrast media and medical imaging solutions, she was appointed as an independent director at the Annual General Meeting held on May 23, 2025. Guerbet also states that she chairs the Audit Committee of the Board, a key body responsible for overseeing financial statements, internal control, risk management, and the quality of both financial and sustainability reporting. This position reflects the confidence placed in her senior-level expertise in financial oversight and organizational governance. Before joining Guerbet, Michèle Lesieur built a long career at Philips, where she held a series of leadership roles across electronics, services, and, most importantly, medical imaging. She led the Sales and Services division of Philips Medical Systems in France from 2000 to 2006, then became Senior Vice President of Philips Healthcare, responsible for Global Sales & Service International for Imaging Systems, as well as Managing Director of BG Imaging Systems for international markets. From 2011 to 2016, she served as CEO of Philips France and Managing Director of Philips Healthcare France. In 2016, she became CEO of Supersonic Imagine, a listed medical imaging company, and ran it until 2020. Guerbet notes that she organized Supersonic Imagine’s sale to U.S.-based Hologic in 2019, highlighting her ability to manage strategic transactions and value-creation processes. Her career demonstrates deep knowledge of healthcare markets, international operations, and growth challenges in medical technologies. She has also served as an independent director for several companies, including Intrasense, Prodways Group, EOS Imaging, Provepharm, and Intelligent Ultrasound, reinforcing her profile as a seasoned governance professional. At Guerbet, her contribution is rooted in independent oversight, financial discipline, and strategic support for a major pharmaceutical and industrial group.